Safety and convenience of cetuximab (cet) and irinotecan (iri) both given every two weeks in metastatic colorectal cancer (mcrc) patients (pts). Pereliminary report
ANNALS OF ONCOLOGY(2007)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
ANNALS OF ONCOLOGY(2007)